These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 11758575)

  • 21. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 22. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The generic drug approval process.
    Rheinstein PH
    Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
    [No Abstract]   [Full Text] [Related]  

  • 24. The application of the patent laws to the drug approval process.
    Coggio BD; Cerrito FD
    Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
    [No Abstract]   [Full Text] [Related]  

  • 25. Epo, by any other name.
    Nature; 2007 Sep; 449(7160):259. PubMed ID: 17882170
    [No Abstract]   [Full Text] [Related]  

  • 26. The right to a jury trial in actions under the Waxman-Hatch Act.
    Coggio BD; Bresnick SA
    Food Drug Law J; 1997; 52(3):259-76. PubMed ID: 10343025
    [No Abstract]   [Full Text] [Related]  

  • 27. Delayed access to generic medicine: a comment on the Hatch-Waxman Act and the "approval bottleneck".
    Patel AN
    Fordham Law Rev; 2009 Nov; 78(2):1075-115. PubMed ID: 19938382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. If it's regulated like a duck ... uncertainties in implementing the patent exceptions of the Drug Price Competition and Patent Term Restoration Act.
    Bloch DJ
    Food Drug Law J; 1999; 54(1):111-26. PubMed ID: 11758554
    [No Abstract]   [Full Text] [Related]  

  • 29. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
    [No Abstract]   [Full Text] [Related]  

  • 30. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
    Steinhauer EH
    Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
    [No Abstract]   [Full Text] [Related]  

  • 32. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The right to a jury trial under the Waxman-Hatch Act--the question revisited and resolved.
    Coggio BD; DeMasi TE
    Food Drug Law J; 2002; 57(1):155-60. PubMed ID: 12118478
    [No Abstract]   [Full Text] [Related]  

  • 34. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS
    Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713
    [No Abstract]   [Full Text] [Related]  

  • 35. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 36. Judicial developments in the US Hatch-Waxman infringement safe harbor.
    Swirnoff AH; Becker DM
    Expert Opin Ther Pat; 2010 Apr; 20(4):451-8. PubMed ID: 20302449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use patents, carve-outs, and incentives--a new battle in the drug-patent wars.
    Rai A
    N Engl J Med; 2012 Aug; 367(6):491-3. PubMed ID: 22873529
    [No Abstract]   [Full Text] [Related]  

  • 38. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 39. Issues in the interpretation of 180-day exclusivity.
    Lietzan E; Korn DE
    Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.